cp-55,940 has been researched along with Colitis in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Andrzejak, V; Body-Malapel, M; Chavatte, P; Desreumaux, P; Djouina, M; El Bakali, J; Lambert, DM; Leleu-Chavain, N; Lemaire, L; Lemoine, A; Mansouri, R; Millet, R; Muccioli, GG; Renault, N; Rigo, B; Tourteau, A | 1 |
1 other study(ies) available for cp-55,940 and Colitis
Article | Year |
---|---|
3-Carboxamido-5-aryl-isoxazoles as new CB2 agonists for the treatment of colitis.
Topics: Animals; Anti-Inflammatory Agents; Cell Proliferation; Colitis; Dextran Sulfate; HT29 Cells; Humans; Interleukin-1beta; Isoxazoles; Male; Mice; Mice, Inbred C57BL; Protein Binding; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Structure-Activity Relationship; Tumor Necrosis Factor-alpha | 2013 |